NDC 66621-0150

ANASCORP

Centruroides (scorpion) Immune F(ab)2 (equine)

ANASCORP is a Intravenous Injection, Powder, Lyophilized, For Solution in the Plasma Derivative category. It is labeled and distributed by Rare Disease Therapeutics, Inc. The primary component is Centruroides Fab2 Antivenin (equine).

• Product ID: 66621-0150_036723fb-cef3-4705-b9c5-ad61049acef5
• NDC: 66621-0150
• Product Type: Plasma Derivative
• Proprietary Name: ANASCORP
• Generic Name: Centruroides (scorpion) Immune F(ab)2 (equine)
• Dosage Form: Injection, Powder, Lyophilized, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2011-08-03
• Marketing Category: BLA / BLA
• Application Number: BLA125335
• Labeler Name: Rare Disease Therapeutics, Inc
• Substance Name: CENTRUROIDES FAB2 ANTIVENIN (EQUINE)
• Active Ingredient Strength: 7 mg/mL
• Pharm Classes: Antivenin [EPC], Antivenins [CS], Passively Acquired Immunity [PE], Venom Neutralization [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 66621-0150-2

1 VIAL in 1 CARTON (66621-0150-2) > 10 mL in 1 VIAL (66621-0150-1)

• Marketing Start Date: 2011-08-03
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 66621-0150-2 [66621015002]

ANASCORP INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA125335
• Product Type: PLASMA DERIVATIVE
• Billing Unit: EA
• Marketing Start Date: 2017-06-27

NDC 66621-0150-1 [66621015001]

ANASCORP INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA125335
• Product Type: PLASMA DERIVATIVE
• Billing Unit: EA
• Marketing Start Date: 2011-08-03

Drug Details

Active Ingredients

Ingredient	Strength
CENTRUROIDES FAB2 ANTIVENIN (EQUINE)	3.8 mg/mL

Pharmacological Class

• Antivenin [EPC]
• Passively Acquired Immunity [PE]
• Venom Neutralization [MoA]
• Antivenins [CS]